REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAÏVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION

Background: Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are associated with similar or lower rates of major bleeding (MB) compared to warfarin. However, few studies have evaluated the MB-related medical costs. This study compared risk of MB and MB-related medical costs